Target intelligence / Profile preview

Gamma-aminobutyric acid type A receptor alpha-1 beta-3 gamma-2 (GABA_A receptor α1β3γ2)

Target
GABA_A receptor α1β3γ2
Molecular classification
Ion channel, Ligand-gated ion channel, Receptor, Cys-loop receptor
01

Overview

The GABA_A receptor α1β3γ2 is a heteropentameric ligand-gated ion channel and the most prevalent subtype of GABA_A receptor in the vertebrate central nervous system [1, 11]. It is composed of two α1, two β3, and one γ2 subunits arranged around a central chloride-selective pore [1, 4]. This receptor mediates fast inhibitory neurotransmission, known as phasic inhibition, by allowing chloride ion influx upon binding of the endogenous neurotransmitter gamma-aminobutyric acid (GABA) [6, 7]. It serves as a primary therapeutic target for a wide range of drugs, including benzodiazepines like diazepam and alprazolam, which act as positive allosteric modulators at the α+/γ2- interface, as well as general anesthetics such as propofol and etomidate [1, 2, 12]. Dysfunction of this receptor complex is implicated in various neurological and psychiatric conditions, including epilepsy, anxiety disorders, and insomnia [1, 7, 11]. Clinical use of drugs targeting this receptor is often limited by safety concerns such as respiratory depression, sedation, and the risk of developing tolerance or dependence [12, 13].

Other names
GABA(A) receptor alpha1beta3gamma2GABRA1-GABRB3-GABRG2 complexBZ1 receptorBenzodiazepine receptor 1Alpha-1 beta-3 gamma-2 GABA-A receptor
02

Mechanism of action

Positive allosteric modulation of GABA-induced chloride currents; direct channel activation at high concentrations of certain anesthetics; competitive antagonism; non-competitive pore blockade.

03

Biological functions

Inhibitory neurotransmissionChloride ion transportSignal transductionPhasic inhibition
04

Disease associations

EpilepsyAnxietyInsomniaDepressionSchizophreniaAutism spectrum disorder
05

Safety considerations

Respiratory depressionSedationToleranceDependenceWithdrawalCognitive impairmentAtaxia
06

Interacting drugs

Diazepam

8 more in the full profile.

07

Biomarkers

EEG beta activity[11C]flumazenil PET imaging[3H]flunitrazepam binding[3H]muscimol binding

Beyond the preview

Go deeper on Gamma-aminobutyric acid type A receptor alpha-1 beta-3 gamma-2 (GABA_A receptor α1β3γ2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma-aminobutyric acid type A receptor alpha-1 beta-3 gamma-2 (GABA_A receptor α1β3γ2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call